ICH Q8–Q12 — Development, Risk, Quality System & Lifecycle

The QbD and lifecycle family: pharmaceutical development (Q8), quality risk management (Q9), the pharmaceutical quality system (Q10), development and manufacture of drug substance (Q11), and lifecycle management (Q12) — treated as one story.

Outline and talking points — the full write-up is still to come. (Grouped by design — for an analysis course these are context; split into separate pages later if the class needs the depth.)

What this page covers

  • Q8 — pharmaceutical development: quality by design (QbD), critical quality attributes (CQAs), design space, control strategy.
  • Q9(R1) — quality risk management: FMEA and friends, and the formality/subjectivity revisions.
  • Q10 — the pharmaceutical quality system: management responsibility, CAPA, change management, management review; how it maps onto ICH’s model.
  • Q11 — development and manufacture of drug substances (small molecule and biotech); starting-material justification.
  • Q12 — lifecycle management: established conditions, the Product Lifecycle Management (PLCM) document, post-approval change categories.
  • The analytical throughline: CQAs drive specifications drive methods; a method is part of the control strategy, and changing it is a managed change under Q10/Q12.

Lecture prep — open items

  • One clean QbD diagram: QTPP → CQAs → CPPs → control strategy.
  • Decide whether Q11 gets real time or a mention.
  • Q12 “established conditions” for an analytical procedure — worked example.